Emerging drugs for hyperlipidemia

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Lipid Metabolism

Background:

• Elevated low-density lipoprotein (LDL) cholesterol significantly increases the risk of coronary atherosclerosis, CHD morbidity, and mortality.
• Lowering LDL cholesterol reduces cardiovascular events and mortality in at-risk individuals and those with established CHD.
• Despite statin efficacy, residual cardiovascular risk remains a significant concern.

Purpose of the Study:

• To review emerging drugs for hyperlipidemia treatment.
• To highlight novel mechanisms targeting lipoprotein metabolism.
• To discuss the potential of new therapies to reduce residual cardiovascular risk.

Main Methods:

• Review of recent data on emerging lipid-lowering drugs.
• Focus on novel mechanisms including inhibition of lipoprotein assembly, enhanced clearance, and modified remodeling/modification.
• Categorization of drugs by their therapeutic targets (e.g., ApoB, MTP, PCSK9, CETP, PPAR).

Main Results:

• Emerging drugs target diverse pathways: lipoprotein assembly (antisense mRNA, MTP inhibitors), clearance (PCSK9 inhibitors, thyroid hormone analogues), remodeling (CETP inhibitors, PPAR agonists), and modification (HO-1, PLA2 inhibitors).
• These novel agents offer alternative or complementary strategies to statins for managing hyperlipidemia.
• The review covers specific examples like dalcetrapib, anacetrapib, GFT-505, aleglitazar, succinobucol, varespladib, and darapladib.

Conclusions:

• Emerging lipid-lowering medications hold promise for more effective reductions in cardiovascular morbidity and mortality.
• These novel therapies may address the unmet need for managing residual cardiovascular risk in patients treated with statins.
• The development of drugs targeting various aspects of lipoprotein metabolism represents a significant advancement in hyperlipidemia treatment.